MX2021007026A - Metodos para mejorar la tolerancia al ejercicio en pacientes con encefalomielitis mialgica. - Google Patents

Metodos para mejorar la tolerancia al ejercicio en pacientes con encefalomielitis mialgica.

Info

Publication number
MX2021007026A
MX2021007026A MX2021007026A MX2021007026A MX2021007026A MX 2021007026 A MX2021007026 A MX 2021007026A MX 2021007026 A MX2021007026 A MX 2021007026A MX 2021007026 A MX2021007026 A MX 2021007026A MX 2021007026 A MX2021007026 A MX 2021007026A
Authority
MX
Mexico
Prior art keywords
methods
patients
myalgic encephalomyelitis
exercise tolerance
improving exercise
Prior art date
Application number
MX2021007026A
Other languages
English (en)
Inventor
David R Strayer
Diane L Young
Thomas K Equels
Original Assignee
Aim Immunotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aim Immunotech Inc filed Critical Aim Immunotech Inc
Publication of MX2021007026A publication Critical patent/MX2021007026A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para tratar a un sujeto con síntomas de encefalomielitis miálgica/síndrome de fatiga crónica que comprenden administrar a un sujeto diana una composición farmacéutica que comprende un ARNbc terapéutico (ARNbct).
MX2021007026A 2018-12-13 2019-11-25 Metodos para mejorar la tolerancia al ejercicio en pacientes con encefalomielitis mialgica. MX2021007026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862778935P 2018-12-13 2018-12-13
PCT/US2019/063048 WO2020123136A1 (en) 2018-12-13 2019-11-25 Methods for improving exercise tolerance in myalgic encephalomyelitis patients

Publications (1)

Publication Number Publication Date
MX2021007026A true MX2021007026A (es) 2021-10-22

Family

ID=69005827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007026A MX2021007026A (es) 2018-12-13 2019-11-25 Metodos para mejorar la tolerancia al ejercicio en pacientes con encefalomielitis mialgica.

Country Status (12)

Country Link
US (1) US11813281B2 (es)
EP (1) EP3893893A1 (es)
JP (1) JP7475702B2 (es)
KR (1) KR20210104782A (es)
CN (1) CN113194963A (es)
AR (1) AR117696A1 (es)
AU (1) AU2019398016A1 (es)
BR (1) BR112021011331A2 (es)
CA (1) CA3123379A1 (es)
MX (1) MX2021007026A (es)
SG (1) SG11202106283SA (es)
WO (1) WO2020123136A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3196563A1 (en) * 2020-09-21 2022-03-24 Aim Immunotech Inc. Compositions and methods for treating cancer
CA3218066A1 (en) * 2021-05-05 2022-11-10 Thomas K. EQUELS Methods and compositions for treating neuroinflammation
WO2023023676A1 (en) * 2021-08-20 2023-02-23 Aim Immunotech Inc. Compositions and methods for treating post-covid conditions of fatigue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
ATE103493T1 (de) * 1988-07-07 1994-04-15 Hem Pharma Corp Diagnose und behandlung chronischer ermuedungserscheinungen.
US5258369A (en) 1988-08-29 1993-11-02 Hem Pharmaceuticals Corporation Treatment of chronic cerebral dysfunction by dsRNA methodology
ES2365847T3 (es) * 2003-10-03 2011-10-11 Veijlen N.V. Uso de derivados del ácido indolacético que aumentan la concentración sérica de igf-1 para la preparación de una composición terapéutica para el tratamiento de diversas enfermedades.
US20110196020A1 (en) * 2008-10-10 2011-08-11 Carter William A Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3)
US8722874B2 (en) 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
WO2010104571A2 (en) * 2009-03-13 2010-09-16 Hemispherx Biopharma, Inc. Treating chronic fatigue syndrome and prolonged qt interval
US8569255B2 (en) * 2011-02-02 2013-10-29 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Post-exposure therapy of influenza A infections
AR093423A1 (es) * 2013-07-19 2015-06-03 Hemispherx Biopharm Inc Metodo de diagnostico y estabilizacion de los sintomas de cfs/me en un paciente

Also Published As

Publication number Publication date
SG11202106283SA (en) 2021-07-29
KR20210104782A (ko) 2021-08-25
CN113194963A (zh) 2021-07-30
WO2020123136A1 (en) 2020-06-18
AU2019398016A1 (en) 2021-07-22
JP7475702B2 (ja) 2024-04-30
US11813281B2 (en) 2023-11-14
CA3123379A1 (en) 2020-06-18
JP2022513905A (ja) 2022-02-09
US20220062321A1 (en) 2022-03-03
BR112021011331A2 (pt) 2021-08-31
AR117696A1 (es) 2021-08-25
EP3893893A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
MX2021007026A (es) Metodos para mejorar la tolerancia al ejercicio en pacientes con encefalomielitis mialgica.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
PH12018502593A1 (en) Combinations of linagliptin and metformin
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2015013939A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2015003048A (es) Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado.
EA201590582A1 (ru) Способы и композиции для лечения мукополисахаридоза типа iiia с использованием интратекального введения
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112022007721A2 (pt) Método para o tratamento da demência
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
EA202193276A1 (ru) Способы лечения холангиокарциномы
BR112012026939A2 (pt) método para tratamento de um paciente sofrendo da perda ou debilitação da visão
BR112019002355A2 (pt) composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
DOP2022000095A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA201500240A1 (ru) Фармацевтическая композиция для коррекции симптомов или лечения астении и/или синдрома хронической усталости